For citations:
Danilov AB, Lila AM, Majidova YN, Gromova OA, Tkacheva ON, Sarvilina IV, Kochish AY, Nazarenko AG, Zagorodniy NV, Minasov TB, Alekseeva LI, Taskina EA, Kotovskaya YV, Dudinskaya EN, Rozanov AV, Solovieva EY, Shavlovskaya OA, Sharov MN, Kamchatnov PR, Rachin AP, Barantsevich ER, Iskra DA, Yakupov EZ, Devlikamova FI, Barulin AE, Nesterova MV, Sakovets TG, Barinov AN, Dolgova IN, Zabolotskikh NV, Zonova EV, Shchepankevich LA, Parfenov VA, Dzhurabekova AT, Khakimova SZ. New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):134-146. (In Russ.) https://doi.org/10.14412/2074-2711-2023-2-134-146
Email this article 